PI3K Inhibition for Squamous Cell Head and Neck Carcinoma

被引：5
|
作者：
Desilets, Antoine [1 ,2 ]
Soulieres, Denis [1 ]
机构：
[1] Ctr Hosp Univ Montreal CHUM, Pavillon C,1000 Rue St Denis, Montreal, PQ H2X 0C1, Canada
[2] Mem Sloan Kettering Canc Ctr, 1275 York Ave, New York, NY 10021 USA
来源：
CANCER JOURNAL | 2022年 / 28卷 / 05期
关键词：
Head and neck squamous cell carcinoma; PI3K inhibitors; targeted therapy; PHOSPHOINOSITIDE 3-KINASE INHIBITOR; I DOSE-ESCALATION; BUPARLISIB BKM120; PACLITAXEL; RECURRENT; CHEMOTHERAPY; COMBINATION; EXPRESSION; RECEPTOR; NIVOLUMAB;
D O I：
10.1097/PPO.0000000000000618
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
The phosphoinositide 3-kinase (PI3K) pathway is aberrantly activated in most head and neck squamous cell carcinomas, making it a prized target for targeted therapy development. Multiple PI3K inhibitors have been studied in early phase trials, with unfavorable risk-benefit ratios in molecularly unselected patient populations. Buparlisib, a potent pan-class I PI3K inhibitor, shows promising efficacy in combination with paclitaxel for advanced head and neck squamous cell carcinoma. Results of the phase III BURAN trial are awaited.
引用
收藏
页码：369 / 376
页数：8
相关论文
共 50 条
  • [41] Immunotherapy in head and neck squamous cell carcinoma: An updated review
    Parmar, K.
    Mohamed, A.
    Vaish, E.
    Thawani, R.
    Cetnar, J.
    Thein, K. Z.
    CANCER TREATMENT AND RESEARCH COMMUNICATIONS, 2022, 33
  • [42] Tertiary lymphoid structures in head and neck squamous cell carcinoma
    Zhu, Jing
    Lu, Hui
    Wang, Kongcheng
    Liu, Baorui
    Yan, Jing
    TRANSLATIONAL ONCOLOGY, 2024, 44
  • [43] P4HA2 contributes to head and neck squamous cell carcinoma progression and EMT through PI3K/AKT signaling pathway
    Wu, Yan-Ling
    Liu, Wan
    Zhao, Tingting
    Jin, Jing
    MEDICAL ONCOLOGY, 2024, 41 (06)
  • [44] Targeting EGFR-PI3K-AKT-mTOR signaling enhances radiosensitivity in head and neck squamous cell carcinoma
    Horn, Dominik
    Hess, Jochen
    Freier, Kolja
    Hoffmann, Juergen
    Freudlsperger, Christian
    EXPERT OPINION ON THERAPEUTIC TARGETS, 2015, 19 (06) : 795 - 805
  • [45] Obesity and Survival After Immune Checkpoint Inhibition for Head and Neck Squamous Cell Carcinoma
    Mastrolonardo, Eric V.
    Llerena, Pablo
    Lu, Joseph
    Nunes, Kathryn
    Choi, Grace K.
    Amin, Dev
    Bridgham, Kelly M.
    Campbell, Daniel
    Philips, Ramez
    Cognetti, David M.
    Luginbuhl, Adam J.
    Curry, Joseph M.
    JAMA OTOLARYNGOLOGY-HEAD & NECK SURGERY, 2024, : 688 - 694
  • [46] The use of pembrolizumab monotherapy for the management of head and neck squamous cell carcinoma (HNSCC) in the UK
    Vasiliadou, Ifigenia
    Grose, Derek
    Wilson, Christina
    Thapa, Alekh
    Donnelly, Olly
    Lee, Elsa
    Leslie, Isla
    Karim, Mahwish
    Hartley, Andrew
    Partridge, Sarah
    Medlow, Katharine
    De Boisanger, James
    Metcalf, Robert
    Williamson, Andrew
    Haridass, Anoop
    Noble, David
    Mactier, Karen
    Walter, Harriet
    Ma, Ning
    De Winton, Emma
    Cohen, Jennifer
    Rayner, Lindsay
    Geropantas, Konstantinos
    Jankowska, Petra
    Mason, Jessica
    Moleron, Rafael
    Laws, Kirsten
    Ulahannan, Danny
    Nallathambi, Chandran
    Michaelidou, Andriana
    Nallamilli, Susanna
    Raouf, Sherif
    Palmer, Kieran
    Bienz, Maya
    Karet, Tracy
    Khalique, Saira
    Paterson, Claire
    Harrington, Kevin
    Bhide, Shreerang
    Kong, Anthony
    INTERNATIONAL JOURNAL OF CANCER, 2024, 155 (05) : 883 - 893
  • [47] Recent insights in the PI3K/Akt pathway as a promising therapeutic target in combination with EGFR-targeting agents to treat head and neck squamous cell carcinoma
    Zaryouh, Hannah
    De Pauw, Ines
    Baysal, Hasan
    Peeters, Marc
    Vermorken, Jan Baptist
    Lardon, Filip
    Wouters, An
    MEDICINAL RESEARCH REVIEWS, 2022, 42 (01) : 112 - 155
  • [48] Eosinophil prognostic scores for patients with head and neck squamous cell carcinoma treated with nivolumab
    Nishikawa, Daisuke
    Suzuki, Hidenori
    Beppu, Shintaro
    Terada, Hoshino
    Sawabe, Michi
    Kadowaki, Shigenori
    Sone, Michihiko
    Hanai, Nobuhiro
    CANCER SCIENCE, 2021, 112 (01) : 339 - 346
  • [49] The PI3K/Akt/mTORC signaling axis in head and neck squamous cell carcinoma: Possibilities for therapeutic interventions either as single agents or in combination with conventional therapies
    Dilmaghani, Nader Akbari
    Safaroghli-Azar, Ava
    Pourbagheri-Sigaroodi, Atieh
    Bashash, Davood
    IUBMB LIFE, 2021, 73 (04) : 618 - 642
  • [50] Enhancing programmed cell death protein 1 axis inhibition in head and neck squamous cell carcinoma: Combination immunotherapy
    Vathiotis, Ioannis A.
    Johnson, Jennifer M.
    Argiris, Athanassios
    CANCER TREATMENT REVIEWS, 2021, 97
12345